Drug Profile

Research programme: cognitive deficits therapeutics - Bionomics

Alternative Names: Kv3.1/3.2 potassium channel activators

Latest Information Update: 30 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

23 Dec 2024 Bionomics re-domiciled from Australia to USA and became wholly owned subsidiary of Neuphoria Therapeutics
01 Dec 2022 Preclinical trials in Cognition disorders in Australia (unspecified route) (Bionomics pipeline, December 2022)
23 Jun 2014 Bionomics and Merck enter into an exclusive research collaboration and license agreement for programme for cognitive dysfunctions associated with Alzheimer's disease and other CNS disorders

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com